



TEL:4006-871-227 Web:www.ybio.net Email:shybio@126.com

YBA139Mu01 10 μ g

Recombinant Tumor Necrosis Factor Related Apoptosis Inducing Ligand (TRAIL)

Organism Species: *Mus musculus* (Mouse)

*Instruction
manual*

FOR IN VITRO USE AND RESEARCH USE ONLY

NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

10th Edition (Revised in Jan, 2014)

[PROPERTIES]

Residues: Met40~Asn291

Tags: Two N-terminal Tags, His-tag and S-tag

Accession: P50592

Host: *E. coli*

Subcellular Location: Membrane; Single-pass
type II membrane protein.

Purity: >90%


Endotoxin Level: <1.0EU per 1 μ g (determined by the
LAL method).

Formulation: Supplied as lyophilized form in 20mM
Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM
DTT, 0.01% sarcosyl, 5% trehalose, and preservative.

Predicted isoelectric point: 7.7

Predicted Molecular Mass: 35.9kDa

Applications: SDS-PAGE; WB; ELISA; IP.





TEL:4006-871-227 Web:www.ybio.net Email:shybio@126.com

(May be suitable for use in other assays to be determined by the end user.)

[USAGE]

Reconstitute in ddH₂O.



TEL:4006-871-227 Web:www.ybio.net

Email:shybio@126.com

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Stability Test: The thermal stability is described by the loss rate of the target protein. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. (Referring from China Biological Products Standard, which was calculated by the Arrhenius equation.) The loss of this protein is less than 5% within the expiration date under appropriate storage condition.

[SEQUENCES]

The sequence of the target protein is listed below.

M YFTNEMQLQ DNYSKIGLAC FSKTDEDFWD STDGEILNRP CLQVKRQLYQ LIEEVLTRTF
QDTISTVPEK QLSTPPLPRG GRPQKVAARI TGITRRNSA LIPISKDGKT LGQKIESWES
SRKGHSFLNH VLFRNGELVI EQEGLYYIYS QTYFRFQAE DASKMVSCK VRTKQLVQYI
YKYTSYPDPI VLMKSARNSC WSRDAEYGLY SIYQGGLFEL KKNDRIFVSV TNEHMLDLQ
EASFFGAFI N

[REFERENCES]

1. Wiley S.R., *et al.* (1995) *Immunity* 3:673-682.
2. Cretney E., *et al.* (2002) *J. Immunol.* 168:1356-1361.
3. Takeda K., *et al.* (2002) *J. Exp. Med.* 195:161-169.
4. Strebel A., *et al.* (2002) *Int. J. Cancer* 100:627-634.